(NASDAQ: ARGX) Argenx Se's forecast annual revenue growth rate of 339.06% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.23%.
Argenx Se's revenue in 2024 is $38,622,826.On average, 12 Wall Street analysts forecast ARGX's revenue for 2024 to be $108,047,876,530, with the lowest ARGX revenue forecast at $101,043,215,181, and the highest ARGX revenue forecast at $117,388,589,153. On average, 12 Wall Street analysts forecast ARGX's revenue for 2025 to be $144,576,143,935, with the lowest ARGX revenue forecast at $121,237,414,763, and the highest ARGX revenue forecast at $174,616,636,261.
In 2026, ARGX is forecast to generate $196,819,719,182 in revenue, with the lowest revenue forecast at $166,395,705,768 and the highest revenue forecast at $260,319,007,933.